logo-loader
viewCannPal Animal Therapeutics Ltd

CannPal Animal Therapeutics teams up with University of Melbourne

A cooperative relationship in the field of veterinary science will be established.

two hands shaking with letter MOU in background
The aim is to complete a pilot study targeting epilepsy in dogs in 2019

CannPal Animal Therapeutics Ltd (ASX:CP1) has entered into a memorandum of understanding (MoU) with the University of Melbourne to research an epilepsy treatment for dogs.

Under the MoU, both parties will work on terms to establish a cooperative relationship in the field of veterinary science to complete a pilot study to determine the efficacy of cannabidiol (CBD) treatment for epilepsy in dogs in 2019.

The MoU builds on CannPal’s current research pipeline which includes the phase Ib study for CPAT-01, a pain control in dogs, and its extension CPAT-01C for cats.

READ:  CannPal Animal Therapeutics receives approval to advance clinical studies

CannPal's managing director Layton Mills said: “This MoU with the University of Melbourne is the latest in a long line of strategic agreements CannPal has entered, to establish the company as a global leader in cannabinoid-derived therapeutics for companion animals.

“It’s further validation of the high-quality research we are undertaking and we look forward to working with the University on this project.”

Cannabidiol has a number of reported health benefits

Cannabidiol is a non-psychoactive compound derived from cannabis with a number of reported health benefits which include anxiolytic, anti-inflammatory, antibacterial and antiseizure properties.

In June 2018, the US Food and Drug Administration (FDA) approved Epidiolex (cannabidiol) oral solution for the treatment of seizures associated with two rare and severe forms of epilepsy in human patients of 2 years of age and older.

This is the first FDA-approved drug that contains a purified drug substance derived from marijuana and the Company is hopeful that similar effects using cannabinoids can be seen in dogs with idiopathic epilepsy.

Quick facts: CannPal Animal Therapeutics Ltd

Price: 0.105 AUD

ASX:CP1
Market: ASX
Market Cap: $9.78 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CannPal Animal Therapeutics Ltd named herein, including the promotion by the Company of CannPal Animal Therapeutics Ltd in any Content on the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

CannPal Animal Therapeutics leveraged to 'lucrative potential' of growing market

CannPal Animal Therapeutics Ltd (ASX:CP1) founder and managing director Layton Mills speaks to Proactive Investors about the innovative pet pharmaceutical company, which operates in the medical cannabis space. "The goal for the company is really to develop products that can address clear,...

on 25/6/18

2 min read